Tatsuya Haze
Overview
Explore the profile of Tatsuya Haze including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
174
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kinguchi S, Ishiga K, Wakui H, Azushima K, Kanaoka T, Kobayashi Y, et al.
Am J Hypertens
. 2025 Mar;
PMID: 40063419
Background: We investigated the effects of sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor (ARNI), on 24-hour blood pressure (BP) and safety for 12 weeks in Japanese patients with non-dialysis advanced...
2.
Haze T, Katsurada K, Sakata S, Kuwabara M, Nishida N, Azegami T, et al.
Hypertens Res
. 2025 Feb;
PMID: 39948181
We conducted a systematic review and meta-analysis to evaluate the effects of intensive versus standard antihypertensive therapy on cardiovascular outcomes in adult patients with hypertension. The primary endpoints were composite...
3.
Ishiga K, Uehara T, Wakui H, Azushima K, Ueda E, Kanai D, et al.
Ther Apher Dial
. 2024 Dec;
PMID: 39737698
Introduction: The efficacy of lipoprotein apheresis (LA) in peripheral arterial disease (PAD) has been primarily attributed to its anti-atherosclerotic effects through the adsorption of lipoproteins. However, the other potential effects...
4.
5.
Fujiwara N, Haze T, Wakui H, Tamura K, Tsuiki M, Kamemura K, et al.
Hypertens Res
. 2024 Oct;
48(2):540-552.
PMID: 39402300
The new Japanese guidelines for primary aldosteronism introduce a category in the judgment of functional confirmatory tests that is called the "borderline range," which is rare in the other international...
6.
Ishiga K, Wakui H, Azushima K, Kanaoka T, Kanai D, Kobayashi R, et al.
Intern Med
. 2024 Sep;
63(23):3157-3163.
PMID: 39343571
Objective Patients undergoing maintenance dialysis are at a higher risk of morbidity and mortality due to severe coronavirus disease 2019 (COVID-19) than the general population. However, longitudinal data regarding this...
7.
Tanoshima R, Inagaki N, Nitta M, Sue S, Shimizu S, Haze T, et al.
Ther Innov Regul Sci
. 2024 Sep;
58(6):1006-1013.
PMID: 39227522
The results of observational studies using real-world data, known as real-world evidence, have gradually started to be used in drug development and decision-making by policymakers. A good quality management system-a...
8.
Sakima A, Akagi Y, Akasaki Y, Fujii T, Haze T, Kawakami-Mori F, et al.
Hypertens Res
. 2024 Jul;
48(2):478-491.
PMID: 38977877
This systematic review and meta-analysis included randomized controlled trials or observational studies that compare digital health interventions (DHIs) for telemedicine/telehealth versus usual care for managing blood pressure (BP) in adults....
9.
Kawano R, Haze T, Fujiwara A, Haruna A, Ozawa M, Kobayashi Y, et al.
Clin Exp Nephrol
. 2024 Jul;
28(12):1282-1289.
PMID: 38970649
Background: Renoprotective effects of sodium glucose transporter 2 (SGLT2) inhibitors, including dapagliflozin, were observed in randomized controlled trials (RCTs). The suspected underlying mechanism is a correction of hyperfiltration, observed as...
10.
Okada K, Haze T, Kikuchi S, Kirigaya H, Hanajima Y, Tsutsumi K, et al.
J Atheroscler Thromb
. 2024 Jun;
31(12):1748-1762.
PMID: 38880605
Aim: Early and intensive low-density lipoprotein (LDL-C)-lowering therapy plays important roles in secondary prevention of acute coronary syndrome (ACS), but the treatment period for further clinical benefit remains undefined. This...